Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35


Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.

Porto I, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimský P, Le Gall N, Zagar AJ, LeNarz LA, Miller D, Montalescot G; ACCOAST Investigators.

JACC Cardiovasc Interv. 2016 May 9;9(9):897-907. doi: 10.1016/j.jcin.2016.01.041.


Developing drugs for use before, during and soon after percutaneous coronary intervention.

Gargiulo G, Moschovitis A, Windecker S, Valgimigli M.

Expert Opin Pharmacother. 2016;17(6):803-18. doi: 10.1517/14656566.2016.1145666. Epub 2016 Mar 3. Review.


Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial.

Geisler T, Droppa M, Gawaz M, Steinhubl SR, Bertrand ME, Lincoff AM, Cequier AR, Desmet W, Rasmussen LH, Hoekstra JW, Bernstein D, Deliargyris EN, Mehran R, Stone GW.

Catheter Cardiovasc Interv. 2016 Aug;88(2):174-81. doi: 10.1002/ccd.26232. Epub 2015 Sep 2.


2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group .

Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29. No abstract available.


Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.

Danchin N, Aïssaoui N.

Cardiovasc Drugs Ther. 2010 Aug;24(4):325-30. doi: 10.1007/s10557-010-6259-3. Review.


Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes.

Bassand JP, Afzal R, Eikelboom J, Wallentin L, Peters R, Budaj A, Fox KA, Joyner CD, Chrolavicius S, Granger CB, Mehta S, Yusuf S; OASIS 5 and OASIS 6 Investigators.

Eur Heart J. 2010 Jan;31(1):50-8. doi: 10.1093/eurheartj/ehp401. Epub 2009 Oct 12.


Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.

Spinler SA, Ou FS, Roe MT, Gibler WB, Ohman EM, Pollack CV, Alexander KP, Peterson ED.

Pharmacotherapy. 2009 Jun;29(6):631-8. doi: 10.1592/phco.29.6.631.


Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Lopes RD, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV Jr, Hoekstra J, Gersh BJ, Stone GW, Ohman EM.

J Am Coll Cardiol. 2009 Mar 24;53(12):1021-30. doi: 10.1016/j.jacc.2008.12.021. Erratum in: J Am Coll Cardiol. 2009 Apr 21;53(16):1473.


Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.

Joyner CD, Peters RJ, Afzal R, Chrolavicius S, Mehta SR, Fox KA, Granger CB, Franzosi MG, Flather M, Budaj A, Bassand JP, Yusuf S.

Am Heart J. 2009 Mar;157(3):502-8. doi: 10.1016/j.ahj.2008.10.028.


Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.

Heer T, Juenger C, Gitt AK, Bauer T, Towae F, Zahn R, Senges J, Zeymer U; Acute Coronary Syndromes (ACOS) Registry Investigators.

J Thromb Thrombolysis. 2009 Oct;28(3):325-32. doi: 10.1007/s11239-008-0294-y. Epub 2008 Dec 20.


Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.

Mahaffey KW, Tonev ST, Spinler SA, Levine GN, Gallo R, Ducas J, Goodman SG, Antman EM, Becker RC, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ, Califf RM; SYNERGY Trial Investigators.

Int J Cardiol. 2010 Mar 4;139(2):123-33. doi: 10.1016/j.ijcard.2008.10.008. Epub 2008 Nov 14.


Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.

Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators.

Circulation. 2008 Nov 11;118(20):2038-46. doi: 10.1161/CIRCULATIONAHA.108.789479. Epub 2008 Oct 27. Erratum in: Circulation. 2008 Dec 16;118(25):e842.


Bleeding and outcome in acute coronary syndrome: insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial.

Yan AT, Yan RT, Huynh T, DeYoung P, Weeks A, Fitchett DH, Langer A, Goodman SG; INTERACT Investigators.

Am Heart J. 2008 Oct;156(4):769-75. doi: 10.1016/j.ahj.2008.05.022. Epub 2008 Jul 21.


Tailored antithrombotic therapy for acute coronary syndromes.

Fitchett D.

Expert Rev Cardiovasc Ther. 2008 Aug;6(7):935-44. doi: 10.1586/14779072.6.7.935. Review.


Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.

Lopes RD, Alexander KP, Marcucci G, White HD, Spinler S, Col J, Aylward PE, Califf RM, Mahaffey KW.

Eur Heart J. 2008 Aug;29(15):1827-33. doi: 10.1093/eurheartj/ehn236. Epub 2008 Jun 2.


Factor Xa inactivation in acute coronary syndrome.

Barantke M, Bonnemeier H.

Curr Pharm Des. 2008;14(12):1186-90. Review.


Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.

Blick SK, Orman JS, Wagstaff AJ, Scott LJ.

Am J Cardiovasc Drugs. 2008;8(2):113-25. Review. Erratum in: Am J Cardiovasc Drugs. 2008;8(6):427.


Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.

Melloni C, Peterson ED, Chen AY, Szczech LA, Newby LK, Harrington RA, Gibler WB, Ohman EM, Spinler SA, Roe MT, Alexander KP.

J Am Coll Cardiol. 2008 Mar 11;51(10):991-6. doi: 10.1016/j.jacc.2007.11.045.


The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.

Pollack CV Jr, Goldberg AD.

J Emerg Med. 2008 May;34(4):417-28. doi: 10.1016/j.jemermed.2007.08.058. Epub 2008 Jan 28. Review.


Supplemental Content

Loading ...
Support Center